FDA Warning Letter to Wholesale Peptide Over Unapproved Prostamax and Gonadorelin

On June 17, 2026, the FDA issued a warning letter to Wholesale Peptide after reviewing the company's website in May 2026. The letter is a single-company action, separate from the telehealth warning-letter wave the FDA posted the previous day.

The FDA stated that Prostamax and Gonadorelin are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act. The agency also stated that no approved applications are in effect for those products.

The letter addressed the company's research use only framing directly. The FDA stated that research use only statements did not override evidence of intended human use drawn from the website itself.

This reasoning matches the position the FDA took in its March 31, 2026 letters to other online peptide sellers. In each case, the agency looked past a research label to the claims and context that showed how the products were presented to buyers.

A warning letter states the FDA position; it is not a seizure, a recall, or a court finding. The regulatory point for readers is consistent across these letters: a product name on a research website does not create an FDA approval, and approval, where it exists, belongs only to a specific approved product and its labeled indication.